JP2020535161A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535161A5
JP2020535161A5 JP2020517388A JP2020517388A JP2020535161A5 JP 2020535161 A5 JP2020535161 A5 JP 2020535161A5 JP 2020517388 A JP2020517388 A JP 2020517388A JP 2020517388 A JP2020517388 A JP 2020517388A JP 2020535161 A5 JP2020535161 A5 JP 2020535161A5
Authority
JP
Japan
Prior art keywords
composition
patient
hypertension
fusion protein
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020517388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535161A (ja
JP7511469B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052795 external-priority patent/WO2019067502A1/en
Publication of JP2020535161A publication Critical patent/JP2020535161A/ja
Publication of JP2020535161A5 publication Critical patent/JP2020535161A5/ja
Priority to JP2023007311A priority Critical patent/JP7598960B2/ja
Application granted granted Critical
Publication of JP7511469B2 publication Critical patent/JP7511469B2/ja
Priority to JP2024209675A priority patent/JP2025023189A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020517388A 2017-09-27 2018-09-26 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。 Active JP7511469B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023007311A JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2024209675A JP2025023189A (ja) 2017-09-27 2024-12-02 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563829P 2017-09-27 2017-09-27
US62/563,829 2017-09-27
PCT/US2018/052795 WO2019067502A1 (en) 2017-09-27 2018-09-26 METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023007311A Division JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Publications (3)

Publication Number Publication Date
JP2020535161A JP2020535161A (ja) 2020-12-03
JP2020535161A5 true JP2020535161A5 (https=) 2021-11-04
JP7511469B2 JP7511469B2 (ja) 2024-07-05

Family

ID=63858139

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517388A Active JP7511469B2 (ja) 2017-09-27 2018-09-26 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2023007311A Active JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2024209675A Pending JP2025023189A (ja) 2017-09-27 2024-12-02 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023007311A Active JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2024209675A Pending JP2025023189A (ja) 2017-09-27 2024-12-02 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Country Status (5)

Country Link
US (2) US12134790B2 (https=)
EP (1) EP3687565A1 (https=)
JP (3) JP7511469B2 (https=)
CA (1) CA3096821A1 (https=)
WO (1) WO2019067502A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CN116406281A (zh) * 2020-05-27 2023-07-07 依诺兹梅制药公司 用于治疗外周动脉疾病的组合物和方法
KR20230047334A (ko) * 2020-05-27 2023-04-07 이노자임 파마, 인코포레이티드 혈관 평활근 세포 증식을 억제하기 위한 조성물 및 방법
IL298853A (en) * 2020-06-09 2023-02-01 Inozyme Pharma Inc Soluble enpp1 or enpp3 proteins and uses thereof
WO2023049864A1 (en) * 2021-09-24 2023-03-30 Inozyme Pharma, Inc. Lyophilized enpp1 polypeptide formulations and uses thereof

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
JPH04292169A (ja) 1991-03-19 1992-10-16 Sekisui Chem Co Ltd ハイブリッド型人工膵臓
US5418618A (en) 1992-03-09 1995-05-23 Mita Industrial Co., Ltd. Tone processing method for forming a halftone image
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
EP0719434B1 (de) 1993-09-15 1997-07-23 Océ Printing Systems GmbH Anordnung zur erzeugung eines rasterbildes auf einem lichtempfindlichen aufzeichunungsträger
AU1518595A (en) 1994-01-14 1995-08-01 Genentech Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
DK1023442T3 (da) 1997-10-16 2011-03-14 Univ Georgia Transgenetiske fugle og fremstilling af proteiner
US5932465A (en) 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
EP1032662B1 (en) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
AU1801899A (en) 1998-12-03 2000-06-19 Histatek, Llc Small peptides and methods for treatment of asthma and inflammation
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
JP3983449B2 (ja) 1999-10-15 2007-09-26 株式会社リコー パルス幅変調回路、光書き込み装置及び画像形成装置
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001062977A2 (en) 2000-02-23 2001-08-30 Pxe International, Inc. Methods and composition for diagnosing and treating pseudoxanthoma elasticum and related conditions
JP2001274989A (ja) 2000-03-27 2001-10-05 Ricoh Co Ltd 画像処理装置及び画像処理方法並びにプリンタ出力装置
DE20121960U1 (de) 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
WO2002012182A1 (fr) 2000-08-08 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Derives de 3-methyl-20-epi-vitamine d
WO2002039994A2 (en) 2000-11-20 2002-05-23 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
EP1438401B1 (en) 2001-09-18 2011-06-15 Synageva BioPharma Corp. Production of a transgenic avian by cytoplasmic injection
CA2462653C (en) 2001-11-07 2016-06-07 Aya Jakobovits Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US9055984B2 (en) 2004-04-21 2015-06-16 DePuy Synthes Products, Inc. Sternal reconstruction system
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US8110660B2 (en) 2004-11-19 2012-02-07 Ono Pharmaceutical Co., Ltd. Soluble ENPP4 protein
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
JP5199077B2 (ja) 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
EP1736553A1 (en) 2005-06-17 2006-12-27 Centre National De La Recherche Scientifique ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
US20090180989A1 (en) 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
US11039942B2 (en) 2006-06-13 2021-06-22 Sino Medical Sciences Technology Inc. Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
EP2097533B9 (en) 2006-11-28 2010-12-22 Proyecto de Biomedicina Cima, S.L. Viral vector and uses thereof
US20080273206A1 (en) 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
PT2662448T (pt) 2007-05-11 2017-03-29 Alexion Pharma Inc Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma
US20100184672A1 (en) 2007-06-18 2010-07-22 Mccarty Owen J T Protein c for use in maintaining hemostasis
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
JP4888439B2 (ja) 2008-05-30 2012-02-29 ブラザー工業株式会社 画像読取装置および原稿サイズ決定プログラム
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
KR101772366B1 (ko) 2011-03-11 2017-08-28 알렉시온 파마슈티칼스, 인코포레이티드 Npp1 융합 단백질
JP2014509617A (ja) 2011-03-29 2014-04-21 ベタ−セル エンフェー 治療薬のカプセル化方法、およびその使用
WO2013074615A1 (en) 2011-11-14 2013-05-23 Yale University Compositions and methods for modulating coagulation
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CA2924259C (en) 2013-09-19 2021-12-21 Universitatsspital Basel Artificial vascular graft
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3234116B1 (en) 2014-12-19 2021-09-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
KR20250078598A (ko) 2015-05-19 2025-06-02 예일 유니버시티 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
FI3373980T3 (fi) 2015-11-12 2025-07-10 The Res Institute At Nationwide Childrens Hospital Menetelmiä lihasdystrofian hoitamiseksi
WO2017087936A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
BR112019002355A2 (pt) 2016-08-05 2019-07-16 Yale University composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
MX2019009812A (es) 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
JP2021523139A (ja) 2018-05-08 2021-09-02 イエール ユニバーシティ 腎石症の進行を遅らせるための組成物および方法

Similar Documents

Publication Publication Date Title
JP2020535161A5 (https=)
Ibraheem et al. Administration strategies for proteins and peptides
JP2020090507A5 (https=)
RU2684398C2 (ru) Состав с постоянным соотношением инсулина гларгина/ликсизенатида
DK2640411T3 (en) INTERLEUKIN-2 FOR SUBLINGUAL ADMINISTRATION TO USE IN TREATMENT OF INFLAMMATION
JP2016516016A5 (https=)
JP2017501154A5 (https=)
McCrystal et al. Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl] acridine-4-carboxamide
JP2017519799A5 (https=)
JP2017500316A5 (https=)
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
EP3137097B1 (en) Treatment and prevention of alzheimer's disease (ad)
JP2014519514A5 (https=)
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
JP2003514622A (ja) 患者中のサイトカインインヒビターを除去するための方法およびシステム
CN114129711B (zh) 度拉糖肽在制备抗肿瘤药物中的应用
JPWO2022009163A5 (https=)
JPWO2020234781A5 (https=)
CN119894507A (zh) 嵌合抗原受体(car)t细胞辅助疗法
Jha et al. Immunotherapy's Promising Potential for Cancer Treatment: Oncology-Immunotherapy for Cancer
JP2021518392A5 (https=)
JP7168228B2 (ja) 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
CN110841069A (zh) 一种含有沙利度胺与抗真菌药物的药物组合物及应用
JPS5821624A (ja) 慢性関節リウマチの治療剤
TW200908997A (en) Treatment of cellular proliferative disorders